Project Details
Goal of the project
The project aims to evaluate and suggest combination of antimicrobials such as antibiotics, lytic phages, phage-borne enzymes, and anti-persister agents (including toxin-antitoxin systems, quorum-sensing network inhibitors, and ppGpp signaling inhibitors) for administration in treatment of infections caused by MDR bacteria. One of the tasks of the project is the creation of a biobank of K. pneumoniae, P. aeruginosa, and A. baumannii strains, and the development of AntiPERS Phage. PHAGES-AntiPERS fit the scope of the call.
Funding acknowledgement
The RMA participates in this project as non-funded partner.
| Short title | Phage Therapy Antipersister strategy |
|---|---|
| Acronym | PHAGES-AntiPERS |
| Status | Active |
| Effective start/end date | 1/04/25 → 31/03/28 |
Collaborative partners
- Royal Military Academy
- Biomedical Research Institute of A Coruña (lead)
- Instituto de Salud Carlos III
- University of Wroclaw
- Hadassah University Medical Center
- Norwich Research Park
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.